Last mentioned: Mar 22, 2026
Clinical Translation
Promising candidates are shared with clinicians for potential off-label use or further clinical study.
Data Analysis
Transcriptomic data is analyzed to identify drugs that normalize the expression of the disease-causing gene.
High-Throughput Screening
The Function platform screens thousands of FDA-approved drugs against these patient-specific cells.
Cell Reprogramming
Patient cells are converted into induced pluripotent stem cells (iPSCs) and then into relevant cell types, like neurons.
Patient Partnership
Rarebase partners with a patient advocacy group to collect biological samples (blood or skin cells).
Rarebase is pioneering a high-throughput drug discovery model that screens existing FDA-approved medications against thousands of rare genetic disorders. By partnering directly with patient advocacy groups, the lab aims to bypass traditional R&D hurdles and find immediate treatments for 'orphan' conditions.
This page surfaces every story mentioning Rarebase across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Rarebase was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |